The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention
J Hepatol. 2021 Jul 30;S0168-8278(21)01954-1. doi: 10.1016/j.jhep.2021.07.025.Online ahead of print.
Naomi F Lange1, Pompilia Radu2, Jean-François Dufour2
Author information
1University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Switzerland. Electronic address: naomi.lange@insel.ch.
2University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland.
Abstract
In many countries worldwide, the burden of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing and preventive strategies are needed to counteract this trend. This review provides an overview of the evidence on preventive strategies in NAFLD-associated HCC. We considered the impact of lifestyle factors such as weight loss, physical activity, smoking, dietary patterns and food items, including coffee and alcohol, on both HCC and NAFLD/NASH. Furthermore, evidence on chemopreventive treatments, including aspirin, anti-diabetic treatments and statins is summarized. The role of adjuvant therapies considered for tertiary prevention of HCC is briefly reviewed.